Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2005

View Archived Issues

Fumaric acid esters show promise in the treatment of multiple sclerosis

Greater efficacy found with a duloxetine/PFMT combination in women with SUI

VEGFR-2/EGFR inhibitor displays efficacy in a mouse model of intestinal cancer

Oxoglaucine exhibits promising antienteroviral spectrum

New data on the therapeutic benefits of ropinirole in RLS

AT1-Mas receptor complex: a novel target for cardiovascular disease involving enhanced Ang II action

Intravesical hyaluronic acid proven effective in the management of urinary tract infections

CHIR-12.12 enters phase I

Equetro available for manic and mixed episodes in bipolar I disorder

Phase II/III MEND-CABG trial recommended to continue

New phase II safety study for BLP25 Liposome Vaccine

SkyePharma and Mundipharma enter DepoBupivacaine agreement

Cypher stent approved for MRI scans immediately following implantation

Jazz Pharmaceuticals to acquire Orphan Medical

NDA planned for orBec in iGVHD

Enrollment completed in study of darusentan for resistant systolic hypertension

Insmed studies SomatoKine for HIV-associated lipodystrophy

Genmab reaches SPA agreement for HuMax-CD4 pivotal study

Specific IGF-IR kinase inhibitor inhibits angiogenesis, enhances sensitivity to chemotherapy

Novel small molecule prevents chemotherapy/radiation-induced side effects

PTC Therapeutics identifies compound inhibiting VEGF expression via a novel mechanism

Array BioPharma presents orally active small-molecule inhibitors of EGFR and/or ErbB-2

Fast track designation for terlipressin in type 1 hepatorenal syndrome

European approval for Aclasta in Paget's disease of the bone

Recent patents describe new treatments for inflammatory and autoimmune diseases

New therapeutic agents for gastrointestinal disorders claimed

Theravance presents novel agents for overactive bladder

New therapeutic agents for cardiovascular diseases reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...